FDA creates a class II category for wearable bone-vibration devices

The Food and Drug Administration has created a device category for wearables that apply mechanical vibration to the skeleton in an effort to protect bone. In a final order published in the Federal Register on 5 November 2026, FDA classified the "wearable vibration device for orthopedic use" into class II, its middle regulatory tier, subject to special controls [s1].

What the device is

FDA defines the new generic type as a wearable device that uses mechanical vibrations, targeted to specific regions of the skeleton, to reduce loss of bone strength or bone mineral density [s1]. The classification is codified in a new regulation at 21 CFR 888.5895, and the order is effective 5 November 2026 [s1]. That identification is the legal definition of the category, and it frames what such a device claims to do: slow the loss of bone, rather than, for instance, treat a fracture or diagnose disease.

How it reached class II

Under US device law, a genuinely new device is placed automatically into class III, the highest-risk tier, which usually requires premarket approval. FDA can instead classify such a device through the "De Novo" process, authorised under section 513(f)(2) of the Federal Food, Drug, and Cosmetic Act [s1]. This order is the outcome of that process: FDA determined that special controls, combined with general controls, provide a reasonable assurance of the device's safety and effectiveness, and the classification was applicable as of 12 January 2024 [s1].

The effect is forward-looking. Once a device type is classified into class II, later products of the same type can generally reach the market through the 510(k) premarket notification pathway rather than automatic class III review [s1]. FDA said the action will "enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens" [s1].

The special controls

A class II classification binds a device to specific controls that address identified risks. For this category FDA named the central risk as accelerated loss of bone strength and bone mineral density — that is, the possibility that a device meant to help could instead do the opposite or simply fail to work [s1]. To mitigate it, the special controls require clinical performance testing demonstrating that the device performs as intended under anticipated conditions of use, and that testing must evaluate the reduction in loss of bone strength or bone mineral density [s1]. A device must comply with the named special controls to fall within the class II classification and avoid automatic placement in class III [s1].

Why the bone-strength claim is the crux

Bone-loss devices sit in a field crowded with wellness claims, from vibration plates to percussive gadgets, most of which make no regulated medical claim at all. What distinguishes this category is the specific claim written into FDA's definition: reducing loss of bone strength or bone mineral density [s1]. Because that is a medical claim, the order requires it to be backed by clinical performance testing that measures the very outcome the device promises [s1]. A consumer gadget that only advertises general "wellness" would not fall into this category, and would not carry its evidence requirement.

General controls still apply

Class II does not mean lightly regulated. Beyond the device-specific special controls, every class II device remains subject to the general controls that apply across the Food, Drug, and Cosmetic Act, including registration, device listing, labelling rules and reporting requirements. FDA's judgement in this order is that those general controls, together with the special controls it has now codified, are jointly sufficient to give reasonable assurance of safety and effectiveness for this device type [s1]. It is that combination, not special controls alone, that FDA relied on in moving the category out of the automatic class III default [s1].

What is settled

What the order fixes is concrete. A dated final order now exists, the device type is class II, the classification lives at 21 CFR 888.5895, the special controls are codified, and the order took effect on 5 November 2026 [s1]. What it does not do is approve any specific product for sale, confirm that any particular device works, or establish how such a device should fit alongside drugs, exercise or other measures used to protect bone. The category sets the regulatory tier and the evidence any such device must meet before it can make its bone-protection claim [s1].